These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 26676832

  • 1. How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.
    Estrada-Ortiz N, Neochoritis CG, Dömling A.
    ChemMedChem; 2016 Apr 19; 11(8):757-72. PubMed ID: 26676832
    [Abstract] [Full Text] [Related]

  • 2. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H, Chemi G, Campiani G, Brogi S.
    Comput Biol Chem; 2019 Dec 19; 83():107105. PubMed ID: 31473433
    [Abstract] [Full Text] [Related]

  • 3. P53 mdm2 inhibitors.
    Khoury K, Dömling A.
    Curr Pharm Des; 2012 Dec 19; 18(30):4668-78. PubMed ID: 22650254
    [Abstract] [Full Text] [Related]

  • 4. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.
    Phan J, Li Z, Kasprzak A, Li B, Sebti S, Guida W, Schönbrunn E, Chen J.
    J Biol Chem; 2010 Jan 15; 285(3):2174-83. PubMed ID: 19910468
    [Abstract] [Full Text] [Related]

  • 5. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
    Pazgier M, Liu M, Zou G, Yuan W, Li C, Li C, Li J, Monbo J, Zella D, Tarasov SG, Lu W.
    Proc Natl Acad Sci U S A; 2009 Mar 24; 106(12):4665-70. PubMed ID: 19255450
    [Abstract] [Full Text] [Related]

  • 6. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
    Zhao Y, Aguilar A, Bernard D, Wang S.
    J Med Chem; 2015 Feb 12; 58(3):1038-52. PubMed ID: 25396320
    [Abstract] [Full Text] [Related]

  • 7. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.
    Zaytsev A, Dodd B, Magnani M, Ghiron C, Golding BT, Griffin RJ, Liu J, Lu X, Micco I, Newell DR, Padova A, Robertson G, Lunec J, Hardcastle IR.
    Chem Biol Drug Des; 2015 Aug 12; 86(2):180-9. PubMed ID: 25388787
    [Abstract] [Full Text] [Related]

  • 8. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A, Leão M, Soares J, Palmeira A, Pinto M, Saraiva L, Sousa ME.
    Med Res Rev; 2016 Sep 12; 36(5):789-844. PubMed ID: 27302609
    [Abstract] [Full Text] [Related]

  • 9. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
    Golestanian S, Sharifi A, Popowicz GM, Azizian H, Foroumadi A, Szwagierczak A, Holak TA, Amanlou M.
    Life Sci; 2016 Jan 15; 145():240-6. PubMed ID: 26746660
    [Abstract] [Full Text] [Related]

  • 10. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C, McDonnell JM.
    Future Med Chem; 2009 Sep 15; 1(6):1075-94. PubMed ID: 21425995
    [Abstract] [Full Text] [Related]

  • 11. Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells.
    Wu W, Xu C, Ling X, Fan C, Buckley BP, Chernov MV, Ellis L, Li F, Muñoz IG, Wang X.
    Cell Death Dis; 2015 Dec 31; 6(12):e2035. PubMed ID: 26720344
    [Abstract] [Full Text] [Related]

  • 12. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
    Czarna A, Popowicz GM, Pecak A, Wolf S, Dubin G, Holak TA.
    Cell Cycle; 2009 Apr 15; 8(8):1176-84. PubMed ID: 19305137
    [Abstract] [Full Text] [Related]

  • 13. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
    Gupta AK, Bharadwaj M, Kumar A, Mehrotra R.
    Top Curr Chem (Cham); 2017 Feb 15; 375(1):3. PubMed ID: 27943171
    [Abstract] [Full Text] [Related]

  • 14. A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction.
    Surmiak E, Twarda-Clapa A, Zak KM, Musielak B, Tomala MD, Kubica K, Grudnik P, Madej M, Jablonski M, Potempa J, Kalinowska-Tluscik J, Dömling A, Dubin G, Holak TA.
    ACS Chem Biol; 2016 Dec 16; 11(12):3310-3318. PubMed ID: 27709883
    [Abstract] [Full Text] [Related]

  • 15. Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors.
    Cheng X, Chen R, Zhou T, Zhang B, Li Z, Gao M, Huang Y, Liu H, Su Z.
    Nat Commun; 2022 Feb 28; 13(1):1087. PubMed ID: 35228542
    [Abstract] [Full Text] [Related]

  • 16. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
    Barakat K, Mane J, Friesen D, Tuszynski J.
    J Mol Graph Model; 2010 Feb 26; 28(6):555-68. PubMed ID: 20056466
    [Abstract] [Full Text] [Related]

  • 17. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
    Dezi C, Carotti A, Magnani M, Baroni M, Padova A, Cruciani G, Macchiarulo A, Pellicciari R.
    J Chem Inf Model; 2010 Aug 23; 50(8):1451-65. PubMed ID: 20726601
    [Abstract] [Full Text] [Related]

  • 18. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM, Czarna A, Rothweiler U, Szwagierczak A, Krajewski M, Weber L, Holak TA.
    Cell Cycle; 2007 Oct 01; 6(19):2386-92. PubMed ID: 17938582
    [Abstract] [Full Text] [Related]

  • 19. Small-molecule MDM2-p53 inhibitors: recent advances.
    Zhang B, Golding BT, Hardcastle IR.
    Future Med Chem; 2015 Oct 01; 7(5):631-45. PubMed ID: 25921402
    [Abstract] [Full Text] [Related]

  • 20. Small molecule inhibitors of the p53-MDM2.
    Hu CQ, Hu YZ.
    Curr Med Chem; 2008 Oct 01; 15(17):1720-30. PubMed ID: 18673221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.